Clinical Trial Update: Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma [Phase 2]

View source ↗

Summary

Phase 2 trial assessing efficacy and safety of risankizumab (BI 655066/ABBV-066) in patients with severe persistent asthma completed with results posted in 2019…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Risankizumab (risankizumab)

Snippet

Sponsor: AbbVie | Conditions: Asthma | Phase 2 | Status: COMPLETED | Results posted: 2019-04-10